Radio-imaging and radio-therapy of cancer using antibodies to HAAH
The present invention is directed to compositions and method for providing radio-imaging and radiotherapy for cancer. In particular, methods for making and using radio-labeled anti-HAAH antibodies for tumor imaging and immunotherapy are provided.
1. A method for killing cancer cells, comprising the steps of:
conjugating a radioisotope to a PAN-622 antibody, an antibody which binds to human aspartyl (asparaginyl) ß-hydroxylase (HAAH), to form a radiolabeled PAN-622 antibody and
contacting cancer cells with the radiolabeled PAN-622 antibody in an amount sufficient to kill the cancer cells, wherein the radiolabeled PAN-622 antibody binds to HAAH, thereby killing the cancer cells.
2. The method of claim 1 , wherein said radioisotope is selected from the group consisting of 213 Bi, 90 Y and 111 In.
3. The method of claim 1 , wherein the cancer cells are leukemia cells.
4. The method of claim 3 , wherein the radioisotope is 213 Bi.
5. A method for treating cancerous tissue in a mammal, comprising the steps of:
conjugating a radioisotope to a PAN-622 antibody, an antibody which binds to human aspartyl (asparaginyl) ß-hydroxylase (HAAH), to form a radiolabeled antibody and contacting cancerous tissue of said mammal with the radiolabeled antibody which binds to HAAH.
6. The method of claim 5 , wherein said radioisotope is 213 Bi.
7. The method of claim 5 , wherein said radioisotope is 111 In.
8. The method of claim 5 , wherein said radioisotope is 90 Y.
9. A radioimmunoconjugate comprising a chelating agent, a radioisotope, and a fully human anti-HAAH PAN-622 antibody.
10. The radioimmunoconjugate of claim 9 , wherein the radioisotope is 213 Bi.
11. The radioimmunoconjugate of claim 9 , wherein the radioisotope is 111 In.
12. The radioimmunoconjugate of claim 9 , wherein said radioisotope is 90 Y.